NCT06229990 Effect of a Furosemide Stress Test-Guided Strategy on Liberation From Continuous Renal Replacement Therapy in Critically Ill Patients With Acute Kidney Injury
| NCT ID | NCT06229990 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Chiang Mai University |
| Condition | Acute Kidney Injury |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2024-01-01 |
| Primary Completion | 2028-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 80 participants in total. It began in 2024-01-01 with a primary completion date of 2028-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Currently, continuous renal replacement therapy (CRRT) is the main modality for renal support in critically ill patients with hemodynamic instability. Most studies have investigated the timing of RRT initiation. However, prolonged CRRT demonstrated the association of many unexpected events, such as catheter-related complications, catheter-related blood stream infection, hypotension, hypothermia, tachycardia, and atrial fibrillation. Up to now, there is a lack of evidence regarding the timing of withholding CRRT. The furosemide stress test (FST) is a tool that is easy to use and has more availability. The investigators aimed to apply FST to evaluate renal recovery compared with standard treatment in critically ill patients undergoing CRRT.
Eligibility Criteria
Inclusion Criteria: * Adult 20 year of age or older * Acute kidney injury (AKI) stage 3 according to Kidney Disease Improving Global Outcomes (KDIGO) classification with oliguria (urine \<400 ml/day) * Initiate CRRT in ICU (medical ICU, surgical ICU, cardiac care unit) for at least 48 hours (time for initiation and modality of CRRT can adjust by clinician) Exclusion Criteria: * Use any inotropic drug (norepinephrine, epinephrine, dopamine, dobutamine) * Blood urea nitrogen (BUN) \>80 mg/dL * Serum K \<3.5 or \>5 mmol/L * Arterial potential of Hydrogen (pH) \<7.3 * Serum bicarbonate (HCO3) \<15 mmol/L * Urine volume \<400 or \>2,100 mL/day * Urine creatinine clearance (CrCl) at 6 hours \>20 mL/min * Previous chronic kidney disease (CKD) stage 5 or estimated glomerular filtration rate (eGFR) \<15 mL/min/1.73 m2 * Previous RRT within 14 days * Kidney transplantation * Obstructive etiology for AKI * Toxin/drug that necessitates RRT * Allergy to furosemide * Moribund with expected death within 24 hours * Pregnancy
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06229990 clinical trial?
This trial is open to participants of all sexes, aged 20 Years or older, studying Acute Kidney Injury. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06229990 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT06229990 currently recruiting?
Yes, NCT06229990 is actively recruiting participants. Contact the research team at jingprit@hotmail.com for enrollment information.
Where is the NCT06229990 trial being conducted?
This trial is being conducted at Chiang Mai, Thailand.
Who is sponsoring the NCT06229990 clinical trial?
NCT06229990 is sponsored by Chiang Mai University. The trial plans to enroll 80 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.